CD274 and breast carcinoma: Future investigations including a larger and more diverse patient cohort are required to confirm the results, and evaluation of additional T-lymphocyte immune markers and activation phenotypes of various immune cells (including PD-1 and PD-L1) is required to more fully define immune profiles of feline mammary carcinoma patients.